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Pigmentary tumors have been known since the antiquity, being called by CELSIUS 
“melas”, due to their black color. In 1806, LAENNEC introduced the term “melanosis” for 
the pigmentary skin disorder, also making a first classification: encapsulated melanosis, 
infiltrative melanosis and diffuse melanosis. 
In 1837, CARSWELL proposed the term melanoma for malignant pigmentary tumors, 
and in 1864 VIRCHOW classified melanomas into three types, depending on their 
macroscopic structure: simple melanoma, characterized by tumor cell agglomerations situated 
in the connective tissue; melanocarcinoma, characterized by alveolar or cord-like 
proliferations; melanosarcoma, characterized by a fusocellular structure. VIRCHOW 
described the structure of mixed melanic and amelanotic tumors. 
In 1969, CLARK et al. published a classification of pigmentary tumors, estimating the 
invasion level of melanoma depending on the degree of involvement of anatomo-
physiological structures of the skin. One year later, in 1970, BRESLOW proposed the 
assessment of the malignancy grade by measuring the maximal tumor invasion thickness. 
The melanocytic system is formed by melanotic cells of epithelioid and dendritic types, 
disseminated among the cells of the epidermal basal layer. These are precursors of 
melanoblasts that migrate from embryonic neural crests up to the skin; the nervous 
(neuroectodermal) origin of the melanocytic system is unanimously accepted 
For the purpose of uniform terminology in human and veterinary oncology, we present 
the corresponding terms used for the various forms of melanogenic tumors, according to 
GOURREAU et al. (1995). 
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Melanogenic tumor lesions in humans and production animals 
(according to GOURREAU et al., 1995) 
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Cell melanocytoma 
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Mixed melanocytoma 
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For this purpose, we propose the following histological classification: 
 Melanocytomas: 
 -intradermal, lentiginous; 
 -junctional naevus; 
 -dermal and/or hypodermal, cellular type, or dermal naevus, fibromatous type; 
 -mixed, junctional and dermal, mixed naevus. 
 Melanomas: 
 -junctional, epithelioid cells; 
 -dermal and/or hypodermal, fusiform cells, and dendritic and spiral cells; 
 -mixed, junctional and dermal, epithelioid and fusiform cells. 
Morphological characteristics. It should be mentioned that histological examination is 
the only one that can establish the malignant or benign nature of a melanic tumor, and that a 
certainty diagnosis is difficult to make, being subject to errors. Morphological data should be 
corroborated with history data regarding the time of appearance of the first melanic lesions, 
the evolution in time, the lymph node aspect, multiple tumor formations, the age and color of 
the animal, etc. 
The presence of melanic tumor cells is histologically found in the epidermis, dermis and 
hypodermis. Tumor cells are grouped into clusters or columns, and sometimes they can 
invade tissues up to the underlying muscles. Tumor melanocytes multiplied in the dermis 
cause the disorganization of the basal layer, they compress the granular layer and induce the 
thickening of the horny layer, with the appearance of necrotic foci surrounded by 
inflammatory reaction. In advanced forms, the epidermis is disintegrated and ulcers occur. 
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Tumor melanocytes in the dermis are frequently grouped around vessels or nerves, into 
a collagen mass with fibroblasts and histiocytes. The intravascular presence of melanocytes is 
a sign of high malignancy. The melanin amount from melanocytes varies widely and does not 
represent a malignancy criterion. Melanic tumor cells have either a fusiform appearance, 
similar to that of fibrosarcomas, or an epithelioid shape, mimicking undifferentiated 
carcinomas. Even in highly malignant melanomas, mitoses are less numerous, but giant cells 
can be noted. Tumor cells have an extremely varied aspect and they are frequently recognized 
by their pigment content and their cluster or nest arrangement. 
In the epidermis, melanocytes show a dark colored, dense nucleus and a clear 
cytoplasm. In the superficial area of the dermis they are cuboid or oval, similar to epithelioid 
cells. In the lower area of the dermis, cells are elongated, with a nucleus similar to fibroblasts. 
In general, the pigment content tends to diminish from the surface towards deeper areas. 
Junctional melanocytes are both a dermal and epidermal component, in an extremely variable 
proportion. 
Melanomas, known by the old nomenclature as malignant melanomas, may develop 
from normal melanocytes from the epidermis and the buccal epithelium, as well as from 
dermal or junctional elements of melanocytes. In dermoepidermal junctional melanomas, a 
considerable junctional activity is noted, with a descending flow of anaplastic melanocytes 
form the epidermis to the dermis. Tumor cells frequently invade the upper epidermis, so that 
the epidermis disintegrates, inducing ulcerations. Reaching the dermis, tumor cells can 
manifest significant pleomorphism, having cuboid or fusiform shapes. 
The diagnosis of a malignant tumor, a melanoma, compared to the benign form, the 
melanocytoma, is difficult, all the more so when prediction is involved. The difficulty consists 
in the differentiation of a junctional melanoma and the early recognition of the malignant 
transformation of the junctional melanocytoma. Another difficult problem is represented by 
diagnosis and the recognition of the malignant transformation of the dermal melanocytoma. 
The presence of mitoses and necrotic foci is indicative of malignancy. At least in the dog, 
fibrous dermal melanocytoma, blue naevus, has a malignant potential. Melanomas can 
metastasize by blood and lymphatic route, regional lymph nodes usually being the first 
affected. Metastases frequently occur in the lungs. 
We will present some morphological aspects that characterise the main melanic tumors.  
The intraepidermal lentiginous melanocytoma is characterized by the presence of 
melanocytes that are located strictly intraepidermally, having the aspect of a pigment spot, 
without malignancy characteristics. However, malignant developments have been noted in 
humans. 
The junctional naevus melanocytoma histologically presents melanocytes grouped in 
3-20 cell nests, having a polygonal or round shape. Melanocytes are located in the epidermis, 
without exceeding the basal membrane. 
The dermal and/or hypodermal melanocytoma of cellular or dermal naevus type 
has no junctional activity, a variable pigment content, and cells have a disorderly 
arrangement, being both melanocytes and melanophages. Mitoses are absent or completely 
sporadic. Tumor formations located in the chorion do not exceed the size of a nut. 
 The epithelioid junctional melanoma is formed by cells similar to those of the 
carcinoma. Cells are grouped densely, resembling the medulla of the carcinoma or they can be 
arranged as lobules or trabeculae. The cytoplasm of melanocytes contains less pigment 
compared to other melanoma types, and nuclei are larger. 
 The dermal and/or hypodermal melanoma with fusiform cells is formed by 
typically bipolar fusiform cells, with variable sizes. Nuclei are elongated, with scarce 
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chromatin, and nucleoli are obvious. The number of mitoses is greater than in other 
melanomas. Cells give the tumor a sarcomatous or fibromatous aspect, against a background 
of reticulin fibers. 
 The dermal and/or hypodermal melanoma with dendritic and spiral cells is 
formed by cells with a dense, disorderly or band-like arrangement, with an extremely high 
melanin content. Cellular details can only be seen after discoloring. Cells have polyhedral or 
round shapes, being present in numerous small dendritic cells. Mitoses are not numerous, but 
necrotic foci are frequently found. 
 The metastasizing mixed, junctional and dermal melanoma, with epithelioid and 
fusiform cells is frequently found on the buccal mucosa or skin. Microscopically, the 
presence of both cellular types is found, with the predominance of one type 
ETIOLOGY. In animals, as well as in humans, the problem of the etiology of 
melanoma still remains at the stage of theories and suppositions, with controversies and 
certainties that are subsequently contradicted partially or totally. A multifactorial etiology 
may be admitted, in which there are favoring determining factors or risk factors. 
The hereditary factor. The hereditary factor seems to be at least for some animal 
species (horses and swine) scientifically documented. Hair depigmentation and melanoma 
tumors, a phenomenon that occurs in Lipizzaner horses, seems to be genetically programmed 
(9,10); “G” factor is responsible for the discoloring of animals, and the pleomorphic effect of 
this factor could also be responsible for the form of melanic tumors. The execution of this 
genetic program must be related to an activity or block of the hormonal, enzymatic, 
immunological or other regulating system (10). 
The intervention of the genetic factor in the development and evolution of melanic 
tumors could be observed in Sinclair pigs; in appearance and development of melanomas, the 
evidence of transmissibility from parents to descendents already exists. The incidence of 
melanomas in Sinclair pigs can be influenced by selection (12). 
Studies of the molecular base of carcinogenesis in melanomas have been oriented in 
three directions:  
- activated oncogenes;  
- cytogenetic analysis of chromosomal abnormalities;  
- analysis of familial forms, with the research of the gene that can favor the 
appearance of uncontrolled melanocyte proliferation (8). 
The hereditary component, as it has been demonstrated in some pathological cases, 
needs the intervention of an ecological factor for the clinical expression of the disease. The 
existence of the hereditary pathological potential allows the understanding of particular 
individual reactions to the aggressive action of ecological factors. 
Irritating factors, of chemical nature, in hamsters, skin melanomas have been 
induced by repeated paintings with carcinogenic substances. 
Congenital neural crest abnormalities, LEVENE (1980) maintains that following 
neural crest abnormalities, melanocytic ectopias would be initiated, which would 
subsequently become proliferation sites of melanic neoplasms. APUD cell system 
intervention in the development of melanocytes, sometimes with uncontrolled proliferations, 
may be supported. 
The melanin production imbalance, are opine that sustain, at least for horses, that 
melanosarcomatosis could be the manifestation of a metabolic abnormality. The role of the 
hereditary factor in the induction of melanotic neoplasms is rediscussed (14). 
The blue naevus, is nothing else than a deposit of melanic pigment seen through the 
transparency of the dermis and epidermis; has been observed more frequently in Terrier dogs. 
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Horses that change their hair color, becoming white or gray, have a tendency to develop 
melanotic spots as blue naevi, which can subsequently become cancerous (LEVENE, 1980) 
Epidemiological data on melanic tumors in animals. Epidemiological data reveal the 
presence of melanic tumors in all vertebrate species (mammals, birds, fish); are commonly 
found in dogs, horses and some breeds of pigs. Incidence is lower in cattle and goats and 
extremely rare in cats. 
In dogs, according to various bibliographic sources, melanic tumors represent between 4 
and 7% of all tumors and between 9 and 20% of all skin tumors. The highest incidence is in 
dogs aged between 7-14 years and more frequently in Terrier, Cocker and Boxer (7, 1, 2, 3). 
In horses, these tumors represent 6-15% of skin tumors approximately 80% of gray 
horses over 15 years old develop skin melanic growths (2, 4, 5, 6). 
In pigs, melanic tumors have been found in 3-5% of the killed pigs, and in some breeds 
incidence exceeds 20; occur congenitally or at a very young age and almost exclusively in the 
Duro-Jersey breed, in dwarf Sinclair and Harmel pigs. 
In cattle, melanic tumors represent less than 2% of all tumors, with the mention that the 
literature reports a high incidence, between 17 and 24% of all skin neoplasms. 
In cats, melanic tumors are extremely rare, representing less than 1% of all tumors and 
approximately 2% of all skin tumors (2). 
Principles of diagnosis in melanic tumors. Histological diagnosis does not pose 
particular problems. Rapid growth, metastases, especially in the lung and lymph nodes 
Difficulties are encountered in the case of amelanotic melanomas 
The following histological criteria are considered: 
-presence of melanic cells under a dispersed, ungrouped form in the depth of the 
epidermis; 
-melanocyte pleomorphism; 
-sporadic presence of tumor cells in the superficial epidermis; 
-presence of an inflammatory infiltrate, in the absence of trauma or infection and 
presence of melanocytes in the lumen of lymphatic or blood vessels; 
-presence of abnormal mitoses and cytonuclear atypias. 
Therapeutic considerations. In malignant melanoma, the following treatment methods 
are used: the surgical method, radiotherapy and chemotherapy, and recently immunotherapy.  
Surgery is the oldest method in the armamentarium of the fight against cancer. This 
method has been improved in time, benefiting from more and more efficient techniques and 
equipment. 
Radiotherapy appeared at the beginning of the century and has developed especially 
after the introduction of high-penetration rays. In tumors, ionizing radiation stops cell division 
and induces the death of cancer cells. 
Chemotherapy, including hormone therapy, prevents cell division and stops 
proliferation. Local cisplatin treatment of mouth melanoma in dogs have good results. The 
use of cimetidine, 2.5 mg/kg per os, every 8 hours, for 2 months up to one year, in three 
horses with multiple melanomas, resulted in a significant decrease in the number and size of 
melanomas (50-90%) (11). 
Immunotherapy, a recently introduced method in the fight against cancer, which is also 
less harmful for the sick organism, needs to be extended, but in the first place experimented 
and improved in animals. Bispecific anticancer immunotherapy by oncolysis is an 
immunological method for the treatment of malignant tumors by regulated and prolonged 
hyperimmunization, due to autologous (autovaccines) or homologous preparations (stock 
vaccines). This bispecificity involves the specific antigenic strengthening of “weak” tumor 
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antigens (inactive alone) by a “strong” viral antigen (inactive alone) that is capable of 
enhancing the “foreign” character of tumor antigens (13). 
All organisms with tumors oppose or tend to oppose an immune resistance to the 
development of malignant tumors. 
The various modalities of anticancer immunotherapy can be synthesized as follows: 
1. Non-specific stimulation of the immune reaction. 
2. Active immunization, with or without an adjuvant, including: 
a) immunization with tumor cells, cell fractions or purified autologous tumor antigens; 
b) immunization with tumor cells, cell fractions or purified homologous tumor antigens. 
3. Passive immunization by: 
a) serum or immunoglobulins of patients in remission or patients who have rejected their 
own tumors; 
b) in the case of leukemia, heterologous anti-lymphocyte serum (directed against 
patients’ malignant lymphoid cells). 
4. Adoptive immunization, carried out: 
a) with lymphocytes of normal individuals; 
b) with lymphocytes of a normal individual immunized against the patient’s tumor; 
c) with lymphocytes of patients in remission or who have rejected their own tumors; 
d) in the case of leukemia, with bone marrow transplant from a healthy individual to a 
patient in whom leukemic cells have been destroyed. 
5. Immunogenetically coded messages: 
a) with homologous or heterologous lymphocytes that have responded to tumor cell 
immunization; 
b) with nucleic acids (RNA) extracted from messanger cells. 
6. Suppression of favoring antibodies: 
a) relative immunodepression by drugs (suppression of antibody formation without the 
suppression of the cellular immunity reaction) 
b) antibody depletion (drainage of the thoracic canal and reinjection of lymphocytes). 
7. Combination of radio-, chemo- and immunotherapy: 
a) tumor mass reduction before immunotherapy; 
b) selective immunodepression of humoral immunity. 
8. Interferon and interferon-inducible double-stranded RNA (13). 
Malignant melanoma is a favorable form for investigations in the direction of neoplasm 
immunity (16). The lysis of malignant melanocytes by the vaccine virus releases masked 
antigens that, reinjected in the patient, accelerate or trigger antibody production (15). 
The use of oncolytic viruses in animal melanoma remains an extremely attractive issue 
that is open to the future. 
 Immunotherapy in cancerous disease is a modality to stimulate the host protective 
possibilities; antitumoral immunity can be obtained by vaccination and also by biological 
response modification, especially by cytokines. Immunotherapy ways are diversified and 
because of these the efficiency is increased, are used therapies with cytokines, monoclonal 
antibodies, chemical imunostimulators, interferon, tumoral necrosis factors, antibodies against 
tumoral grow factor, antiangiogrnetic factors, and in last year’s was developed studies 
regardind a vast range of vaccines. On the surface of tumoral cells are neoantigens, that are 
transformation antigens tumoral specific or transformation antigens tumoral associated, that 
are not compulsory specific (Baba 2002). 
 Tumoral immunotherapy present two types of repay: humoral and cellular. Important 
is antigen presenting cells ability to process and present tumor associated peptidic antigens, 
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for imonological recognition of tumoral cells. Antigen presenting cells are: macrophages, 
Langherhans epithelial cells, dendritic cells and B cells.  
 Tumoral defense cellular mediated comprise T citolitic lymphocytes, NK cells and 
macrophages. T cells are specific bounding on MHC1 receptors and destroy tumoral cell by 
releasing perforins and by apoptosis induced by FAS. 
 In antitumoral vaccination therapy the following types whose used: 
 1. Polyvalent vaccines   obtained on cells cultures, present the following advantages:  
 Are anautologes, they have many cells lines, hat make that some antigens to be 
 commune with other tumors 
 Is not needed for processing melanic cells developed by the patient 
Desavantage: 
 Are inefficient because usually immune response is waist on irrelevant antigens  that 
 are not present in the patient tumor 
 Long time patient survive was not relevant 
 Imune response maybe improved by using some adequate adjutants; so future use of 
 polyvalent vaccines will be limited.  
 2. Autologus vaccines, presents two types: death cells vaccines and recombined 
autologus cells vaccines. 
 Death or viable cells vaccines require a reduced manipulation comparative with 
recombined autologus vaccines; the tissue is stored from the patient; the stored tissue is 
proceed then reinjected with different types of adjuvant. The advantage of those vaccines is to 
have a high degree of analogy with tumor cells of the patient. Immune response is lethal, both 
on vaccine cells and for wild tumor cells.  
 Recombined DNA cell vaccines are used for improvement of immune response. For 
example, IL-2, CM-CSF or other cytokines, can be used to determine melanocitic tumor cells 
that are ectopic producers of potent imunomodulator substances. The advantage of these 
vaccines is that can be realized from the patient cells, and the majority of antigens will be 
reliable. The disadvantage is that the method obtains a reduced viable tumor cells. 
 3. Peptide vaccines have in their composition peptide epitopes; in the case of 
melanocitic vaccines are amino acid substance, derived from tumor proteins. 
 The advantage of vaccines derived from peptide epitopes is that, they could be made 
in large quantities and to have a reliable price.  
 The disadvantage is the difficulties of vaccines realization; a low number of epitopic 
targets are known; another major disadvantage is the HLA restriction, a vaccine can’t be 
bound in antigenic locus of binding MCH1 receptor, and make the vaccine useless. 
 Theoretically, peptide vaccines could be a solution, but is necessary other studies and 
other precise technologies. 
4. “Nud”DNA vaccines are the latest vaccines obtained against melanoma; there are 
differences from the recombined DNA vaccines, represented by a faster exogenous DNA 
appearance in vivo than in vitro, and there is not necessary autologus tumor cells. The 
response of biologic changers and other proteins to be expresses are inserted in a plasmid 
vector that is capable to show exogenous proteins in mammal cells. The plasmids are inserted 
in skeletal muscle or subcutaneous tissue, to infect host cells from the respective area with 
recombined plasmids. In this way there is a local “storehouse” of ectopic expressed protein. 
The adjuvant inserted in the same time with plasmids, will stimulate immune response in 
vaccine components. The codified protein from the plasmid could be an epitope of antigenic 
response or a series of epitopes. 
 52 
The advantage of the vaccine, there is no necessity of autologus tumor cells, and DNA 
manipulation is no necessary; there are possibilities of massive production with minimal 
administrative necessities. DNA vaccines are the most studied from the vaccines. 
The inconvenient of the vaccines is the difficulty to maintain in time appropriate tissue 
expression levels of the codified proteins. 
5. Dendritic cell vaccines are considered useful; provided from peripheral blood, 
could be in vitro stimulated to obtain antigen presenting cells. The peripheral blood can serve 
like a source of antigen presenting cells, which can be useful in vitro with a relevant peptide 
antigen, and then reinjected. In these vaccines is not necessary tumor tissue, the peripheral 
blood being the only involved autologus tissue.  
The disadvantage are the same like in the other peptide vaccines; the necessity of 
specialized immunology laboratory, equipped to process and to manipulate dendrite cells. 
Biologic response changers are frequent associated with vaccination technology; those 
molecules are immune response mediators.  
The stimulation factor of macrophage-granulocyte colony determines the 
transformation of dendrite cells in antigen presenting mature cells, and in this way to increase 
the endogenous antigen presentation; also, this is a vaccination strategy. 
Interleukins are intracellular signal molecules, with the role of communication 
between the lymphocytes. Interleukins are important mediators of immunologic response that 
could be utilized to increase the responses to vaccine antigens. 
IL-2 is the main early signal molecule for immune response. IL-2 was utilized for in 
vitro stimulation of peripheral vascular lymphocytes, and for in vitro stimulation of 
intratumor lymphocytes, but the results are variable; it was used as ectopic protein expressed 
in cell vaccines with recombined DNA.  
IL-2 is involved in stimulation of helper lymphocyte differentiation in Th1 type, 
which is much more important in cellular mediated tumor defense, comparative with helper 
lymphocyte Th2, that represent the other major pathway of helper cells differentiation. 
Interferon, IFN-g is the most utilized in vaccine therapy. The major role is to activate 
the macrophages and to induce B cell stimulation to produce antibody; it is used like 
independent antitumor therapy or like adjuvant. 
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